semaglutide bmi 26 🚨 @TheLancet RCT: Weekly #semaglutide cut heavy drinking (–41% vs –26% placebo) in alcohol use disorder + obesity. Promising for #AddictionMedicine—more research needed. 🔗 https://t.co/20nNz8iohn @NIH @NIAAAnews @WHO @NovoNordisk #GLP1 @EASLnews Long-term weight loss effects of

Key Highlights: 48 PSGs for products with no approved ANDAs (25 complex products) 39 PSGs for complex products (6 new, 33 revised) Therapies for COPD, opioid overdose, type 2 diabetes, major depressive disorder, and more Notable PSGs: Ensifentrine inhalation suspension (COPD, RLD: OHTUVAYRE) Naloxone hydrochloride nasal spray (Opioid overdose, RLD: REZENOPY) Semaglutide oral tablet (Type 2 diabetes, RLD: RYBELSUS) Trazodone hydrochloride ER oral tablet (MDD, RLD: OLEPTRO) Link : By publishing PSGs, FDA continues to promote innovation in generic development while advancing public health and patient access to cost-effective medicines

PMID:36291616

Key points about the study include: It focuses on a GLP-1/GIP injection for adults who are overweight or obese

They can help you weigh the risks and benefits and may be able to direct you to a reputable pharmacy if they believe it's an appropriate option for you

Read the study here

And the central GLP-1 thirst suppression can mask your body need for water